According to an announcement from Genentech, Lucentis has been approved by the FDA for treating macular edema following retinal vein occlusion (RVO)
Here is Genentech’s news release:
FDA Approves Genentech's Lucentis (Ranibizumab Injection) for the Treatment of Macular Edema Following Retinal Vein Occlusion
Genentech, Inc., a member of the Roche Group, announced today (6/22/10) that the U.S. Food and Drug Administration (FDA) has approved Lucentis (ranibizumab injection) for the treatment of macular edema following retinal vein occlusion (RVO). The FDA approved this new indication after a six-month Priority Review.
"This approval provides an important new medicine for people experiencing (Read more...)